Nalagenetics, a spin off from A*STAR’s GIS, was recently featured in the Business Times on 25 March 2022 for raising US$12.6 million in a Series A funding round.
Founded in 2016, Nalagenetics is a biotechnology company focused on personalised screening and intervention. It aims to provide affordable and actionable end to end genetic testing that is relevant to local populations. The company has four product pillars: Clinical Decision Support for physicians, genetic tests, Knowledge Base and algorithms to generate clinically actionable reports, and Patient Engagement.
For more information, please visit http://www.nalagenetics.com.